November 17, 2017 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”)
A global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that it has acquired international licensing rights for IsoDerm™ as well as five other proprietary pharmaceutical compounds to be delivered by the patented Direct Effects Technology™, a back of the neck delivery system from its developer Dr. Ronald Aung-Din, MD. Dr. Aung-Din is a board-certified neurologist by the American Board of Psychiatry and Neurology and a recognized leader in Cannabidiol (CBD) research and its neurological benefits.
With this revolutionary non-systemic delivery system, a topical cream is applied to the back of the neck (at the hairline) which is then picked up by the free nerve endings located in the dermis of the skin for a highly effective delivery of the compound.
“We are pleased to be moving forward with this long-anticipated transaction that gives Isodiol the international rights to the patent for specific compounds,” said Marcos Agramont, CEO of Isodiol. “We utilize the back of neck technology in our IsoDerm Direct Effects Cream where it has proven to be an extremely effective method of delivering fast relief from neurologic, psychiatric and pain conditions, without concerns of systemic side effects and drug interactions. We look forward to incorporating Dr. Aung-Din’s technologies in the development of a pipeline of products that may have significant application in the treatment of conditions that include Parkinson’s Disease, Peripheral Neuropathy, Cluster Headaches and others significant conditions. We continue to sponsor Dr. Aung-Din’s remarkable work in Autism and will continue our efforts to support the families affected by this condition.”
The Company is required to pay a one time licensing fee of $300,000.00 USD payable over 180 days along with continued minimum royalty payments predicated on product and territories.
For more information on Isodiol, please visit Isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia, and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
North 6th Agency
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.